

# Togo

Population 2015

7.3 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.46 (0.28–0.7)	6.4 (3.8–9.5)
Mortality (HIV+TB only)	0.2 (0.047–0.47)	2.8 (0.64–6.4)
Incidence (includes HIV+TB)	3.8 (2.7–5.1)	52 (37–69)
Incidence (HIV+TB only)	0.82 (0.53–1.2)	11 (7.2–16)
Incidence (MDR/RR-TB)**	0.13 (0–0.28)	1.8 (0–3.8)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.23 (0.11–0.36)	1.2 (0.61–1.9)	1.5 (0.72–2.2)
Males	0.23 (0.14–0.32)	2.1 (1.5–2.7)	2.3 (1.7–3)
Total	0.46 (0.31–0.62)	3.3 (2.7–4)	3.8 (2.7–5.1)

TB case notifications, 2015	
Total cases notified	2 671
Total new and relapse	2 613
- % tested with rapid diagnostics at time of diagnosis	3%
- % with known HIV status	100%
- % pulmonary	87%
- % bacteriologically confirmed among pulmonary	91%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	69% (52–96)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.18 (0.1–0.29)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	561	21%
- on antiretroviral therapy	511	91%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			79 (0–170)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	12% (7–19)	
% notified tested for rifampicin resistance	0%	55%	80
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 8, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2014	88%	2 415
Previously treated cases registered in 2014	76%	162
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	56%	16
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	40% (37–44)

TB financing, 2016	
National TB budget (US\$ millions)	3.5
Funding source: 7% domestic, 46% international, 47% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New cases


Previously treated cases

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically